Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, offered insight to NBC10 about Leqembi, which has been granted full approval by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. The drug is indicated for those with mild cognitive impairment or the mild dementia stage of Alzheimer’s.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH